Panelists discuss offering guidance to parents and caregivers experiencing atopic dermatitis for the first time, emphasizing the importance of education on managing flare-ups, proper skin care routines, and setting realistic treatment expectations while also seeking support from health care professionals to navigate the challenges of the condition.
Panelists discuss when to consider adding or switching agents for atopic dermatitis, highlighting alternative treatments for pediatric patients such as biologics and Janus kinase (JAK) inhibitors, and emphasize the importance of tailoring treatment decisions based on efficacy and patient response, citing studies such as Blauvelt 2023, Keow & Abu-Hilal 2024, and JADE EXTEND. They also explore emerging systemic agents such as nemolizumab (IL-31 receptor antagonist) and rocatinlimab (anti-OX40), which have the potential to significantly affect treatment approaches based on promising early trial results.
“In some cases, that meant that we could actually go after the primary pathology or the primary cause of the condition in a way that we never would have thought of before."
Panelists discuss the prevalence of treatment-refractory moderate to severe atopic dermatitis, noting factors such as intolerance or inability to use high-potency topical agents as common reasons for treatment failure, and emphasize the importance of considering alternative agents or switching treatments when necessary, particularly in pediatric patients, with biologics and Janus kinase (JAK) inhibitors being key options as evidenced by studies such as Blauvelt 2023, Keow & Abu-Hilal 2024 , and JADE EXTEND.
Panelists discuss treatment expectations for newer systemic agents, highlighting data on efficacy onset and persistence, including rapid improvement in pruritus with dupilumab by week 2 (SOLO trials), early Investigator Global Assessment (IGA) and Eczema Area and Severity Index (EASI)-75 improvement with lebrikizumab by week 2 to 4 (ADvocate trials), and EASI-75 improvement with tralokinumab by week 4 (ECZTRA 6 trial), emphasizing the importance of setting realistic expectations with patients and caregivers regarding the onset of action and duration of treatment.
Genetic research is revealing that up to 35% of cerebral palsy cases have an identifiable genetic cause, leading to earlier diagnoses and potential precision medicine treatments.
Peter S. Jensen, MD, comments on the challenges primary health care providers may face when it comes to mental health treatment in pediatrics, and provides screening tools to consider to combat these challenges.
In this discussion, leading experts weigh in on the importance of scientific integrity, proactive advocacy, and the crucial role of vaccinations in pediatric health.
Panelists discuss managing comorbidities and mitigating atopic march in adolescent and adult patients, focusing on the importance of early intervention and coordinated care to prevent the progression of atopic diseases and improve long-term health outcomes.
Panelists discuss the role of newer agents, including biologics/monoclonal antibodies (dupilumab, tralokinumab, lebrikizumab) and Janus kinase (JAK) inhibitors (abrocitinib, baricitinib, upadacitinib), in the treatment of moderate to severe atopic dermatitis, emphasizing their effectiveness in improving outcomes for patients who do not have adequate control with conventional therapies.
Panelists discuss the 2023 American Academy of Allergy, Asthma & Immunology/ American College of Allergy, Asthma & Immunology (AAAAI/ACAAI) Joint Task Force guidelines, highlighting treatment options with strong recommendations and high certainty of evidence, including biologics/monoclonal antibodies (dupilumab, tralokinumab, lebrikizumab) and Janus kinase (JAK) inhibitors (abrocitinib, baricitinib, upadacitinib) for atopic dermatitis management.
Panelists discuss the goals of treating atopic dermatitis, focusing on symptom control and quality of life, with treatment differing for children and adults, and emphasize using assessment tools such as Eczema Area and Severity Index (EASI)-75/90, Investigator Global Assessment (IGA), and itch scores alongside patient-reported outcomes to guide decisions while also considering disease severity and the impact of atopic comorbidities in treatment approaches.
Tina Tan, MD, FAAP, FIDSA, FPIDS, discusses the severity of the current respiratory virus season and stresses the importance of vaccinations to protect against influenza, COVID-19, RSV, and more.
Nurse practitioner Donna Hallas, PhD, PPCNP-BC, CPNP, PMHS, FAANP, FAAN underscores how critical simple, but factual, conversations can be with parents when it comes to pediatric care.
Panelists discuss the diagnosis and referral process for patients with pediatric atopic dermatitis (AD) from both the dermatologist and allergy perspectives, including when a child should be referred to a dermatologist and the importance of a multidisciplinary approach to care for optimizing AD management, with insights on the roles each team member plays in patient care.
Panelists discuss the patient journey for patients with pediatric atopic dermatitis (AD) and their caregivers, from initial presentation through to diagnosis, emphasizing the challenges and emotional aspects that families experience throughout the process.
Panelists discuss the diagnostic criteria for atopic dermatitis (AD), highlighting challenges in diagnosis due to the disease’s heterogeneity across factors like age, skin color, and other variables, and explore how this complexity can lead to misdiagnosis or late diagnosis; they also share tips for diagnosing AD, determining disease severity, and incorporating patient-reported outcomes into severity assessments, while examining how advances in treatment and understanding have shaped current perspectives on AD severity.
Panelists discuss the pathophysiology of atopic dermatitis (AD), focusing on the role of type 2 inflammation, and explore how AD can serve as an entry point to the atopic march in children, leading to other allergic diseases such as food allergies, asthma, and allergic rhinitis, including early indicators that may predict future comorbidities.
Based on recent reports, norovirus outbreaks in the 2024-2025 seasonal year is above the range reported from the 2012-2020 and 2021-2024 seasonal years.
Robert Frenck, MD, offers several practical tips to use when discussing pediatric vaccination among vaccine-hesitant parents.
Principal investigator Lewis Romer, MD, of Johns Hopkins Medicine joined us to discuss the actively-recruiting MoD PAH trial, and explains the role the pediatrician can play in care and recruitment.
Susan Carnell, PhD, highlights the nuanced relationship between social media use and binge eating in adolescents, noting the importance of addressing addictive behaviors and seeking support when needed.
Principal investigator Lewis Romer, MD, of Johns Hopkins Medicine joined us to discuss the actively-recruiting MoD PAH trial assessing mono vs dual therapy for pediatric PAH.
Results from a recent study revealed that compulsive and addictive elements can contribute to the risk of disordered eating. Study investigator Susan Carnell, PhD, explains these findings.
Robert Frenck, MD, explained why 2024 was a big step in the right direction for RSV prevention, and emphasized the importance of vaccination against preventable diseases.
Susan Carnell, PhD explains social media addiction symptoms, but not time on social media, were cross-sectionally and prospectively associated with binge eating.
Russell Libby, MD, FAAP highlights some key benefits of roflumilast 0.15%, approved in 2024 to treat AD in patients aged 6 years and older.
Contemporary Pediatrics' editorial advisory member Russell Libby, MD, FAAP, highlights 2024 FDA approval of epinephrine nasal spray (Neffy) in this video interview.
Greg Forlenza, MD, highlights data from the CLVer trial that included advanced diabetes technology in newly diagnosed T1D patients.
"Tapinarof comes in with that mixture of the short-term studies and longer-term studies intermittently, giving us a nice, effective alternative non-steroid for eczema across the ages."
